Charles Hugh-Jones, Volastra CEO
Oncology specialist Volastra brings in PhI drug from Amgen, nabs $60M in Series A
Almost a year after inking a billion-dollar biobucks deal with Bristol Myers Squibb, NYC biotech Volastra Therapeutics is linking up with two other pharma giants …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.